Clinical trials · Illinois
Myeloproliferative Neoplasm clinical trials in Illinois
We’re tracking 8 recruiting myeloproliferative neoplasm studies with a site in Illinois — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Chicago, IllinoisAges 18 years+ - NCT07008118RecruitingPhase 1
Study of INCA035784 for certain blood cancers
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Chicago, IllinoisAges 18 years+ - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Normal, IllinoisAges Up to 25 years - NCT06291987RecruitingPhase 1
Ivosidenib with ruxolitinib for advanced MPN with IDH1 mutation
This trial tests a combination of two targeted drugs, ivosidenib and ruxolitinib, for people with advanced myeloproliferative neoplasms (MPNs) that have an IDH1 gene mutation. The goal is to see if this treatment can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chicago, IllinoisAges Any age - NCT04064060RecruitingPhase 3
Long-term safety follow-up for luspatercept study participants
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
Chicago, IllinoisAges 18 years+ - NCT05745285Recruiting
LLS care support program for blood cancer patients
This study looks at whether LLS services and support improve outcomes and the day-to-day experience of care for people with leukemia, lymphoma, myeloma, MDS, or MPN. It’s mainly about matching you to the right support and following your progress for 6 months.
Chicago, IllinoisAges 18 years+
Myeloproliferative Neoplasm trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting myeloproliferative neoplasm studies listed above.
- University of Chicago · 5 studies
- Advocate Children's Hospital - Oak Lawn
- Advocate Children's Hospital - Park Ridge
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Carle at The Riverfront
- Carle BroMenn Medical Center
- Carle Cancer Center
- Carle Physician Group-Effingham
What taking part in a myeloproliferative neoplasm study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Myeloproliferative Neoplasm trials in other states
Common questions
- Are there myeloproliferative neoplasm clinical trials in Illinois?
- Yes. We're currently tracking 8 recruiting myeloproliferative neoplasm studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a myeloproliferative neoplasm study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a myeloproliferative neoplasm trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New myeloproliferative neoplasm studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.